ImmuneOnco Biopharmaceuticals Receives NMPA Approval for Lupus Nephritis Phase II Study
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541), a China-based biopharmaceutical company, has announced receiving approval from...
Clinical trial approval / initiation
Jiangsu Kanion Pharmaceutical Gets NMPA Clearance for Oncolytic Virus Product KYS202003A
Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced that it has received clinical clearance...
Sichuan Biokin Pharmaceutical’s BL-M08D1 ADC Receives NMPA Approval for Clinical Trials
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...
Huadong Medicine Receives FDA Clearance for HDM1005 Clinical Study in Obstructive Sleep Apnea
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clearance from...
Huadong Medicine’s Arcalyst Receives NMPA Approval for Cryopyrin-Associated Periodic Syndromes
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving marketing approval from the National...
Jiangsu Kanion Pharmaceutical Secures NMPA Approvals for KYHY2302 and KYHY2303
China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced receiving separate clinical trial approvals...
Phil Rivers Technology Secures IND Approval for PR00012 from NMPA’s CDE
Beijing-based Phil Rivers Technology Co.,Ltd, a high-tech platform company incubated by the Institute of Computing...
Jiangsu Hengrui Medicine’s SHR-1819 Receives NMPA Approval for Atopic Dermatitis Clinical Trial
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that it has received clinical trial...
Sichuan Huiyu Pharmaceutical’s HY-2003 Approved for Clinical Trials by China’s NMPA
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...
Nasal-Phyto Pharmaceutical Receives FDA Clearance for First-Ever Olfactory Drug-Device Combo
China-based Nasal-Phyto Pharmaceutical Technology Group Co., Ltd has announced receiving clinical clearance from the US...
Insilico Medicine Gets FDA Approval for Clinical Study of ENPP1 Inhibitor ISM5939
China’s generative artificial intelligence (AI)-driven biotech company, Insilico Medicine, has announced that it has received...
Shenzhen Kangtai Begins Phase I Clinical Trial for 20-Valent Pneumococcal Vaccine
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the enrollment of the...
Sichuan Kelun-Biotech Receives NMPA Clearance for SKB501 Clinical Trial in Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that it has received clearance from...
Lepu Medical Technology Gains NMPA Approval for Obesity and Diabetes Treatments MWN109 and MWN105
China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease...
GeneQuantum Healthcare’s GQ1011 (AMB302) Receives FDA Approval for Clinical Study
China-based GeneQuantum Healthcare, a leading developer of antibody drug conjugates (ADCs), has announced that it...
Henlius Biotech Initiates Phase III Study for HLX22 in Gastric Cancer Treatment
Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced the dosing of the first patient...
Base Therapeutics’ NK510 Receives US FDA Clearance for Advanced Solid Tumor Studies
Shanghai-based cell therapy specialist Base Therapeutics has achieved clearance from the US Food and Drug...
China Resources Double-Crane Gets NMPA Approval for Semaglutide Biosimilar Clinical Trial
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced that it has received clinical...
First Patient Dosed in Abbisko’s Phase II Trial of ABSK061 and ABSK043 in FGFR2/3 Altered Tumors
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the first patient dosing in...
Jiangsu Hengrui Receives NMPA Approval for HRS-6208 Solid Tumor Clinical Study
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...